Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768363 · ClinicalTrials.gov registry record · Phase 2
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
A Phase 2 study of Prostate Cancer, sponsored by Candel Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT02768363 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Candel Therapeutics. The registered enrollment target is 187 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02768363, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Candel Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate cancer. CAN-2409 involves the use of aglatimagene besadenovec to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. CAN-2409 has been well tolerated in previous trials in patients with prostate cancer and other tumor types. Biochemical, pathologic and immune responses have been demonstrated in newly diagnosed and recurrent prostate cancer. The hypothesis is that CAN-2409 can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the CAN-2409 or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance evaluations.
Conditions Studied
Interventions
- BIOLOGICAL aglatimagene besadenovec
- BIOLOGICAL placebo
- DRUG valacyclovir
Study Locations (20)
Texas
- San Antonio VA Healthcare System - San Antonio
- Woodland Center - The Woodlands
- Texas Urology Specialists - Tomball
Illinois
- Jesse Brown VA Medical Center - Chicago
- The University of Chicago - Chicago
New York
- Advanced Radiation Centers of New York (Integrated Medical Professionals) - North Hills
- Associated Medical Professionals of NY, PLLC - Syracuse
Oregon
- VA Portland Health Care System - Portland
- Oregon Urology Insitute - Springfield
Pennsylvania
- Lancaster Urology - Lancaster
- Allegheny Health Network-Triangle Urological Group - Pittsburgh
Colorado
- Foothills Urology - Golden
Louisiana
- Southeast Louisiana Veterans Health Care System - New Orleans
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2016-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02768363
The ClinicalTrials.gov registry entry for NCT02768363 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which aglatimagene besadenovec is the first listed.
NCT02768363 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT02768363 about?
NCT02768363 is a clinical study titled "Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)". The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate cancer. CAN-2409 involves the use of aglatimagene besadenovec to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an im...
What is the current status of trial NCT02768363?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2016-05. Estimated completion is 2026-12.
What conditions does trial NCT02768363 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02768363?
The interventions under investigation include: aglatimagene besadenovec (BIOLOGICAL), placebo (BIOLOGICAL), valacyclovir (DRUG).
Who is sponsoring clinical trial NCT02768363?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02768363 being conducted?
This trial has 20 study locations across Colorado, Illinois, Louisiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.